Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Biomarker Analysis in a Phase II Study of Sunitinib in Patients with Advanced Melanoma.

Anticancer research - 1 Dec 2015

Decoster Lore, Vande Broek Isabelle, Neyns Bart, Majois Françoise, Baurain Jean François, Rottey Sylvie, Rorive Andrée, Anckaert Ellen, De Mey Johan, De Brakeleer Sylvia, De Grève Jacques

Abstract excerpt

AIM: To investigate the efficacy of sunitinib in patients with advanced melanoma and to correlate angiogenic biomarkers with response and survival. PATIENTS AND METHODS: We performed a phase II study in patients with advanced pre-treated melanoma. The primary endpoint was tumor response. Blood samples for biomarker analysis including vascular endothelial growth factor (VEGF), and its receptors VEGFR1 and -2,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Endpoint Determination
Share to Neovascularization, Pathologic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Pregnancy Proteins

Share to Proto-Oncogene Proteins c-kit

Share to Pyrroles

Share to Sunitinib

Share to Vascular Endothelial Growth Factor Receptor-1

Share to Vascular Endothelial Growth Factor Receptor-2

Source

Identifiers

PMID: 26637913

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Biomarker Analysis in a Phase II Study of Sunitinib in Patients with Advanced Melanoma.PMID 26637913Read ↗

Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma.Semantic proximity Read ↗

Targeting SRPK1 to control VEGF-mediated tumour angiogenesis in metastatic melanomaSemantic proximity Read ↗

Phase II trial of vorinostat in advanced melanoma.Semantic proximity Read ↗

Phase II study of the Multikinase inhibitor of angiogenesis, Linifanib, in patients with metastatic and refractory colorectal cancer expressing mutated KRAS.Semantic proximity Read ↗

A phase II study of gefitinib in patients with metastatic melanoma.Semantic proximity Read ↗

Sunitinib in Patients With Breast Cancer With FGFR1 or FGFR2 Amplifications or Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study.Semantic proximity Read ↗

Angiogenesis: pathological, prognostic, and growth-factor pathways and their link to trial design and anticancer drugs.Semantic proximity Read ↗

Evaluation of efficacy and safety markers in a phase II study of metastatic colorectal cancer treated with aflibercept in the first-line setting.Semantic proximity Read ↗

Evaluation of polymorphisms in angiogenesis-related genes as predictive and prognostic markers for sunitinib-treated metastatic renal cell carcinoma patients.Semantic proximity Read ↗

Biomarkers of angiogenesis and their role in the development of VEGF inhibitors.Semantic proximity Read ↗

Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma.Semantic proximity Read ↗

Evaluation of KRAS mutations, angiogenic biomarkers, and DCE-MRI in patients with advanced non-small-cell lung cancer receiving sorafenib.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.